HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teeling, J. L. Articles by van de Winkel, J. G. J. Search for Related Content PubMed PubMed Citation Articles by Teeling, J. L. Articles by van de Winkel, J. G. J.

The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20¹

Jessica L. Teeling^2,, Wendy J. M. Mackus^2,*, Luus J. J. M. Wiegman^*, Jeroen H. N. van den Brakel^*, Stephen A. Beers, Ruth R. French, Tom van Meerten, Saskia Ebeling, Tom Vink^*, Jerry W. Slootstra^¶, Paul W. H. I. Parren^*, Martin J. Glennie^3,*, and Jan G. J. van de Winkel^*,

^* Genmab, Utrecht, The Netherlands; Tenovus Research Laboratory, Cancer Sciences Division, School of Medicine, University General Hospital, Southampton, United Kingdom; Department of Haematology and Immunotherapy Laboratory, Department of Immunology, University Medical Center, Utrecht, The Netherlands; and ^¶ Pepscan Systems BV, Lelystad, The Netherlands

We have previously defined a panel of fully human CD20 mAb. Most of these were unexpectedly efficient in their ability to recruit C1q to the surface of CD20-positive cells and mediate tumor lysis via activation of the classical pathway of complement. This complement-dependent cytotoxicity (CDC) potency appeared to relate to the unusually slow off-rate of these human Abs. However, we now present epitope-mapping data, which indicates that all human mAb bind a novel region of CD20 that may influence CDC potency. Epitope mapping, using both mutagenesis studies and overlapping 15-mer peptides of the extracellular loops of CD20, defined the amino acids required for binding by an extensive panel of mouse and human mAb. Binding by rituximab and mouse CD20 mAb, had an absolute requirement for alanine and proline at positions 170 and 172, respectively, within the large extracellular loop of CD20. Surprisingly, however, all of the human CD20 mAb recognize a completely novel epitope located N-terminally of this motif, also including the small extracellular loop of CD20. Thus, although off-rate may influence biological activity of mAb, another critical factor for determining CDC potency by CD20 mAb appears to be the region of the target molecule they recognize. We conclude that recognition of the novel epitope cooperates with slow off-rate in determining the activity of CD20 Ab in activation of complement and induction of tumor cell lysis.

This article has been cited by other articles:

				A. K. Gopal, O. W. Press, S. M. Wilbur, D. G. Maloney, and J. M. Pagel Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab Blood, August 1, 2008; 112(3): 830 - 835. [Abstract] [Full Text] [PDF]

				S. E. Lacy, P. J. DeVries, N. Xie, E. Fung, R. R. Lesniewski, and E. B. Reilly The Potency of Erythropoietin-Mimic Antibodies Correlates Inversely with Affinity J. Immunol., July 15, 2008; 181(2): 1282 - 1287. [Abstract] [Full Text] [PDF]

				P. V. Beum, M. A. Lindorfer, F. Beurskens, P. T. Stukenberg, H. M. Lokhorst, A. W. Pawluczkowycz, P. W. H. I. Parren, J. G. J. van de Winkel, and R. P. Taylor Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis J. Immunol., July 1, 2008; 181(1): 822 - 832. [Abstract] [Full Text] [PDF]

				C. A. Walshe, S. A. Beers, R. R. French, C. H. T. Chan, P. W. Johnson, G. K. Packham, M. J. Glennie, and M. S. Cragg Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling J. Biol. Chem., June 20, 2008; 283(25): 16971 - 16984. [Abstract] [Full Text] [PDF]

				A. Hagenbeek, O. Gadeberg, P. Johnson, L. Moller Pedersen, J. Walewski, A. Hellmann, B. K. Link, T. Robak, M. Wojtukiewicz, M. Pfreundschuh, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial Blood, June 15, 2008; 111(12): 5486 - 5495. [Abstract] [Full Text] [PDF]

				B. Li, S. Shi, W. Qian, L. Zhao, D. Zhang, S. Hou, L. Zheng, J. Dai, J. Zhao, H. Wang, et al. Development of Novel Tetravalent Anti-CD20 Antibodies with Potent Antitumor Activity Cancer Res., April 1, 2008; 68(7): 2400 - 2408. [Abstract] [Full Text] [PDF]

				B. Coiffier, S. Lepretre, L. M. Pedersen, O. Gadeberg, H. Fredriksen, M. H. J. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study Blood, February 1, 2008; 111(3): 1094 - 1100. [Abstract] [Full Text] [PDF]

				S.-Y. Wang, E. Racila, R. P. Taylor, and G. J. Weiner NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement Blood, February 1, 2008; 111(3): 1456 - 1463. [Abstract] [Full Text] [PDF]

				D. A. Rider, C. E.G. Havenith, R. de Ridder, J. Schuurman, C. Favre, J. C. Cooper, S. Walker, O. Baadsgaard, S. Marschner, J. G.J. vandeWinkel, et al. A Human CD4 Monoclonal Antibody for the Treatment of T-Cell Lymphoma Combines Inhibition of T-Cell Signaling by a Dual Mechanism with Potent Fc-Dependent Effector Activity Cancer Res., October 15, 2007; 67(20): 9945 - 9953. [Abstract] [Full Text] [PDF]

				J. Du, H. Wang, C. Zhong, B. Peng, M. Zhang, B. Li, S. Huo, Y. Guo, and J. Ding Structural Basis for Recognition of CD20 by Therapeutic Antibody Rituximab J. Biol. Chem., May 18, 2007; 282(20): 15073 - 15080. [Abstract] [Full Text] [PDF]